Shares of Kamada Ltd. (NASDAQ:KMDA) rose 1.9% on Wednesday . The stock traded as high as $4.20 and last traded at $4.20, with a volume of 67,520 shares traded. The stock had previously closed at $4.12.

KMDA has been the topic of several research analyst reports. Zacks Investment Research raised shares of Kamada from a “hold” rating to a “buy” rating and set a $4.50 target price on the stock in a research report on Thursday, August 4th. TheStreet downgraded shares of Kamada from a “hold” rating to a “sell” rating in a research report on Thursday, June 9th.

The firm’s market cap is $151.13 million. The company’s 50 day moving average is $3.91 and its 200-day moving average is $3.83.

Kamada (NASDAQ:KMDA) last posted its earnings results on Tuesday, August 2nd. The company reported ($0.04) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.04). The firm had revenue of $19.10 million for the quarter, compared to analysts’ expectations of $18.50 million. On average, analysts predict that Kamada Ltd. will post ($0.11) earnings per share for the current fiscal year.

Kamada Ltd. is an Israel-based biopharmaceutical company, which develops, produces and markets therapeutics, based on chromatographic purification technology. It offers bio-therapeutics for human use, such as specialty proteins, specific immunoglobulins, and other prescription medicines. The Company’s product line includes intravenous AAT for chronic replacement therapy in individuals with congenital alpha-1 antitrypsin deficiency; KamRAB for prophylaxis of rabies infection; KamRho-D IM for prophylaxis of Rh hemolytic disease of the newborn; KamRho-D IV for treatment of immune thrombocytopenic purpura; and IVIG, a replacement therapy in primary and secondary immune therapy.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.